Docetaxel
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Charles Drew University of Medicine and Science
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06615752CT.gov Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT07225946CT.gov A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06863272CT.gov A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | — | Recruiting | — | — | — |
NCT06551324CT.gov A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | — | Active Not Recruiting | — | — | — |
NCT05627752CT.gov Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | — | Unknown | — | — | — |
NCT06353386CT.gov Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | — | Recruiting | — | — | — |
NCT05848011CT.gov A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT04918810CT.gov Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
Show 25 more trialsShow fewer
NCT05169684CT.gov A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT05084859CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04666129CT.gov Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04015622CT.gov PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | — | Active Not Recruiting | — | — | — |
NCT04404140CT.gov A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | — | Terminated | — | — | — |
NCT04381832CT.gov Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03700099CT.gov Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | — | Unknown | — | — | — |
NCT04028388CT.gov ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT03517969CT.gov M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03903835CT.gov ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03582475CT.gov Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | — | Active Not Recruiting | — | — | — |
NCT03419442CT.gov Multi-academic Center Study of Xofigo Patients | — | Completed | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03442556CT.gov Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | — | Terminated | — | — | — |
NCT03696186CT.gov Selective Treatment According to Molecular Subtype of Prostate Cancer | — | Unknown | — | — | — |
NCT02565901CT.gov Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03761225CT.gov Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT02095717CT.gov Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) | — | Terminated | — | — | — |
NCT01234025CT.gov Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | — | Completed | — | — | — |
NCT01106352CT.gov A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT01083615CT.gov A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT00675545CT.gov A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients | — | Completed | — | — | — |
NCT00411528CT.gov Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00459186CT.gov The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | — | Completed | — | — | — |
NCT00151073CT.gov Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Charles Drew University of Medicine and Science | P3 | BB · 64 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →